Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 4/20 | 0.62 |
| ▸ | WNT3A | P56704 | 4/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698182 | 1.00 | CTNNB1 (0.62) | CTNNB1WNT3ANR4A2KMT2AALDH1A1 | |
| SCHEMBL30089541 | 0.92 | CTNNB1 (0.70) | CTNNB1WNT3AKMT2AMEN1PARP1 | |
| SCHEMBL29062364 | 0.92 | CTNNB1 (0.70) | CTNNB1WNT3AKMT2AMEN1PARP1 | |
| SCHEMBL2743419 | 0.89 | HDAC3 (0.58) | CTNNB1WNT3ANR4A2KMT2AMEN1 | |
| SCHEMBL8533612 | 0.85 | CTNNB1 (0.62) | CTNNB1WNT3AKMT2AMEN1PARP1 | |
| SCHEMBL10790435 | 0.84 | CTNNB1 (0.65) | CTNNB1WNT3AKMT2AMEN1PARP1 | |
| SCHEMBL1421021 | 0.83 | SMN1; SMN2 (0.58) | CTNNB1WNT3AKMT2AMEN1PARP1 | |
| SCHEMBL2027904 | 0.83 | CTNNB1 (0.59) | CTNNB1WNT3AKMT2AALDH1A1MEN1 | |
| SCHEMBL10788703 | 0.83 | CTNNB1 (0.64) | CTNNB1WNT3AKMT2AMEN1PARP1 | |
| SCHEMBL15980082 | 0.82 | CTNNB1 (0.63) | CTNNB1WNT3AKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114605272-B | Preparation method of (R) -fluoxetine and derivatives thereof | 中国科学技术大学 | 2023-09-08 | — | — | CN | disclosed |
| CN-114605272-A | Preparation method of (R) -fluoxetine and derivative thereof | 中国科学技术大学 | 2022-06-10 | — | — | CN | disclosed |
| WO-2021003295-A1 | MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| EP-1737857-A1 | PYRAZOLO[3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| EP-1100769-B1 | AMINOMETHYLCARBOXYLIC ACID DERIVATIVES | AKZO NOBEL NV (NL) | 2002-12-04 | — | — | EP | disclosed |
| US-6410592-B1 | THERAPY FOR CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS | AKZO NOBEL N.V. (NL) | 2002-06-25 | — | — | US | disclosed |
| EP-1100769-A1 | AMINOMETHYLCARBOXYLIC ACID DERIVATIVES | Akzo Nobel N.V. (NL) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000007978-A1 | AMINOMETHYLCARBOXYLIC ACID DERIVATIVES | AKZO NOBEL N.V. (NL) | 2000-02-17 | — | — | WO | disclosed |
| US-5831073-A | Ion triggered alkylation of biological targets by silyloxy aromatic agents | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-11-03 | — | — | US | disclosed |
| US-5493012-A | Ion triggered alkylation of biological targets by silyloxy aromatic agents | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-02-20 | — | — | US | disclosed |
| US-5296350-A | Ion triggered alkylation of biological targets by silyloxy aromatic agents | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0115133-B1 | SPIRO-3-HETERO-AZOLONES FOR TREATMENT OF DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1989-01-25 | — | — | EP | disclosed |
| US-4556670-A | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0115133-A1 | Spiro-3-hetero-azolones for treatment of diabetic complications | PFIZER INC. (US) | 1984-08-08 | — | — | EP | disclosed |
| US-3947460-A | SEDATIVES-HYPNOTIC, TRANQUILIZER | SANDOZ, INC. (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | CTNNB1 2010/4885WNT3A 1476/4885NR4A2 287/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | CTNNB1 2372/4885WNT3A 2717/4885NR4A2 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.